Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (309)	6/18/1999 11:09:00 AM
From: harkenman	Respond to of 3557

Stock up 4% just on your posting. Yo've got magic. I love it.

To: Dr. John M. de Castro who wrote (309)	6/18/1999 11:19:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Thanks John. Seams interesting scientific stuff, still majority of it was already known (I didn't read full article so I may be bit out of line here) about Angio-x functions in neovascularization and tumor growth. Investor do not buy, not anymore, this kind of story. What we need is clear statement from REGN: what is their business plan in regards the Angio-x proteins and how they will implement this plan??? In PRnews they wrote hints like: <<In particular, our findings support drug development based on blocking VEGF action, which Regeneron and others are aggressively pursuing.>> How they are blocking VEGF action??? What agent? or <<This may provide the opportunity to use Angiopoietin-2 as a diagnostic tool to allow imaging of small tumors and metastases, and perhaps even as a handle to allow targeting of chemotherapeutic agents specifically to tumor tissue.>> Angio-2 + WHAT for imaging??? ... and is TIE-2 selective (as natural Angio-2 receptor) expressed on tumor cells to allowed designee targeted Angio-2+chemo agents??? Miljenko